| --- | --- | |---------------------------------------|--------------------| | | | | | | | | | | | | | Oppenheimer 29 th Annual Healthcare | | | Conference | | | March 20, 2019 | | | | | | Investor materials | MED-US-DSU-1900037 | Cautionary statements 2 This presentation contains forward-looking statements, including, but not limited to, statements related to the safety, efficacy and therapeutic value of DSUVIA™ (sufentanil sublingual tablet, 30 mcg) and ZALVISO® (the sufentanil sublingual tablet system); ...

Call Start: 16:30 January 1, 0000 5:19 PM ET AcelRx Pharmaceuticals, Inc. (ACRX) Q4 2018 Earnings Conference Call March 7, 2019, 4:30 pm ET Company Participants Raffi Asadorian - CFO Vince Angotti - CEO Pam Palmer - CMO Conference Call Participants Ashley Ryu - RBC Brandon Folkes - Cantor Fitzgerald Vamil Divan - Credit Suisse Ed Arce - H.C. Wainwright & Company Roger Song - Jefferies Michael Higgins - Ladenburg Thalmann David Buck - B.Riley FBR Leland Gershell - Oppenheimer Operator Welcome to the AcelRx F ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-K ☑ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2018 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-35068 ACELRX PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 41-2193603 (State or other jurisdiction of inc ...